Linezolid Induced Twice Pure Red Cell Aplasia in a Patient with Central Nervous System Infection after Allogeneic Stem Cell Transplantation

Wenqing Hu\textsuperscript{a}, Bing Shi\textsuperscript{a}, Lihui Liu\textsuperscript{a}, Shengke He\textsuperscript{b}, Liping Ye\textsuperscript{a}, DengMei Tian\textsuperscript{a} and Yongqing Zhang\textsuperscript{a*}

\textsuperscript{a}Department of Hematology, The 309\textsuperscript{th} Hospital of PLA, Beijing, 100091, China.\textsuperscript{b}Hebei North University, Zhangjiakou, Hebei Province 075000, China.

Abstract

Linezolid (LZD), severed as the first oxazolidinone antibiotic, was active against multidrug-resistant gram-positive strains. LZD can induce thrombocytopenia, anemia and leukocytopenia. Currently, reports on pure red cell aplasia (PRCA) cases induced by LZD are relatively rare (4-7). In this paper, we reported a patient with PRCA twice induced by LZD. A 37-year-old man was diagnosed with myelodysplastic syndrome (MDS) and underwent allo-HSCT from an unrelated donor with ABO blood type and leukocyte antigen (HLA)-matching. After HSCT for 2 years, the patient suffered from refractory fever and headache. He was first treated with empirical antifungal agent and antibiotics for central nervous system (CNS) infection, but then changed to LZD therapy for little effect. Twenty-eight days after LZD treatment, the symptom improved significantly but the hemoglobin declined to 70 g/L and the reticulocyte level was only 0.23%. The LZD therapy was stopped and the fever and headache symptoms reoccurred 1 week latter. Then, erythropoietin (EPO) and halved dosage of LZD were used for treatment. The CNS infection and the anemia symptom relieved gradually and the level of hemoglobin and reticulocyte declined again. After blood transfusion, the half dose of LZD was sustained without anaemia recovery. In summary, patients with anemia, myelosuppressants history or potential abnormal proliferation of T cells may suffer PRCA with long term LZD treatment. The monitoring of complete blood count and reticulocyte count were necessary during LZD therapy. If the clinical condition permits, LZD dosage reduction and blood transfusion should be considered.

Keywords: Linezolid; Pure red cell aplasia; Hematological toxicities; Hematologic stem cell transplantation; Oxazolidinone antibiotic.

Introduction

Linezolid (LZD), the oxazolidinone antibiotic, is widely used for treating the infections of gram-positive organisms that have resistance to some other antibiotics. In addition, LZD is applied for allogeneic hematopoietic stem cell transplantation (HSCT) settings widely (1). Anemia and thrombocytopenia induced by LZD hematological toxicities are common in patients (1-4), especially in those with long-term treatment of LZD. The most common cause of pure red cell aplasia (PRCA) was the mismatched ABO blood types between donors and recipients (5-7). However, reports concerning LZD-induced PRCA were rare (8-11). PRCA can lead to anemia, reticulocytes level decline (less than...
and various stages of erythroid lineages decrease, especially the absence of erythroid precursor cells (12). Patients who underwent allogeneic hematologic stem cell transplantation (allo-HSCT) were susceptible to microorganism infection such as the gram-positive organism infection. LZD was widely used for preventing microorganism infection for patients after HSCT. Here, we reported a patient who underwent PRCA twice during long-term LZD treatment for central nervous system infection after allo-HSCT for MDS. We aimed to share some treatment experience and prevention strategies for analogous cases.

**Case report**

The patient and his parents had given the informed consent prior to the inclusion in the study. All human studies have been approved by Chinese Ethics Committee and performed in accordance with the ethical standards. A 37-year-old man was diagnosed with myelodysplastic syndrome (MDS) in 2010. The primary symptoms for the patient were pale face (as the first symptom), anemia and thrombocytopenia. The bone marrow smear detected the dysplasia of three lineages presenting with obvious proliferation of 6.5% myeloblast and 7% promyelocyte. The chromosome analysis showed complex abnormalities: 46, XY, add (1) (p36), add (6) (p25), del (17) (q23) (11) /46, XY (3). Gene sequencing revealed that this patient presented with TKD (tyrosine kinase domain) mutation. The percentage of WT1/ABL and CBFB/MYH11 were 4.99% and 0.299%, respectively. MDS presented in this patient was classified to MDS-RAEB-I according to the classification of World Health Organization (WHO) and intermediate-2 by International Prognostic Scoring System (IPSS). The patient had received allo-HSCT from a human leukocyte antigen (HLA)-matched unrelated donor for 4 months without any other treatment.

The patient and donor showed the identical ABO blood type. Before allo-HSCT, the preparative conditioning regimen consisted of Cyclophosphamide (Cy) 120 mg/kg and total body irradiation (TBI) 10 Gy. In the procedure of transplantation, the total dose of mono-nucleated cells (MNC) and CD34+ cells infused were 4.9×10⁹/kg and 8.27×10⁹/kg, respectively. The sustained engraftment of neutrophils and platelets was administrated at day 16.

Two years after HSCT, the patient suffered from refractory fever and headache for around 1 month. According to bio-chemical cerebrospinal fluid (CSF) test, he was diagnosed with central nervous system (CNS) infection without any pathogen detection. The empirical antifungal agent and antibiotics had little effect on the fever and headache of the patient, which included broad-spectrum drugs for gram-negative organisms and vancomycin (VCM) for gram-positive ones.

After changing drugs into LZD on October 18, 2012, the symptoms of fever and headache in the patient were gradually improved and the routine CSF test showed that CNS infection was relieved but the cerebrospinal fluid was still abnormal. However, the fever and headache symptoms reoccurred 1 week after stopping LZD treatment. According to the consultation from other related departments in our hospital, we considered it was probably CNS mycobacterium tuberculosis infection and then the anti-tuberculosis (TB) treatment with rifampicin, isoniazid, ethambutol and pyrazinamide was applied to suppress the return of fever and headache. Nevertheless, the patient with fever and headache continued to deteriorate after anti-TB therapy for 2 weeks, so the regimen was turned into LZD therapy on October 14th. Then the symptoms of fever and headache were improved again as well as the CSF test result.

Complete blood count monitoring showed the hemoglobin was progressively declined from 128 g/L to 70 g/L since LZD was used for 28 days. The reticulocyte proportion was 0.23% and its absolute value was 0.005×10¹²/L. Bone marrow aspiration examination confirmed the presence of a hypo-proliferative anaemia with erythroid cells absence but without testing dysplasia or leukemia. The only concomitant medication was hepatoprotective drugs. Hemoglobin gradually increased to 117 g/L at day 24 after stopping LZD treatment. Thus, LZD was reused for treatment. The anemia relapsed 2 weeks later and the hemoglobin
level was declined to 77 g/L after 6 weeks. At this time, the reticulocyte proportion was 0.21% and its absolute value was $0.005 \times 10^{12}$/L. To remedy the anemia symptom, erythropoietin (EPO, 1wu, twice a week) was added and the dosage of LZD was halved. But there was no effect on anemia symptom and the anemia continued to deteriorate. After LZD was reused for 52 days, the hemoglobin concentration decreased to 66 g/L. The bone marrow smear examination was performed and the smear showed that there were marrow proliferation and obvious decrease of erythroid cells. But the dysplasia in cell lineages and leukemic cells was not observed.

The complete donor chimerism in the patient was confirmed by chimerism analysis. Then the patient accepted blood transfusion immediately and 1 month later, the hemoglobin level was only 55 g/L due to the progressive anemia. So, we conducted blood transfusion once again and the hemoglobin level rebounded to 82 g/L 10 days later. The halved dosage of initial LZD was continually administrated but the anemia symptom did not deteriorate anymore. LZD treatment was completely stopped after a full course of 5.5 months and the hemoglobin recovered to 110 g/L after 2 weeks (Figure 1). The proportion of reticulocyte was 1.65% ($0.05 \times 10^{12}$/L). The bone marrow examination showed a proliferative state and a decline of intermediate erythroblast.

Discussion

LZD is a new oxazolidinone antibiotic that can inhibit the synthesis of bacterial RNA and protein (13). Previous clinical researches indicated that long-term LZD treatment could result in diarrhea, headache, nausea and bone marrow suppression. The evidence about the close association of LZD and pure red cell aplasia (PRCA) was insufficient. To our knowledge, only 6 literatures documented about the LZD-induced PRCA (8-11), among which one case who suffered from MDS and PRCA within 1 month after allo-HSCT was reported (11). The case reported in the present study was different from that one in the suffering time (more than 2 years after HSCT) and the treatment course.

PRCA is a type of anemia with only red blood cell aplasia, which can be induced by thymoma, lymphoproliferative diseases, virus infections, autoimmune diseases and medication such as phenytoin sodium, EPO and chloramphenicol. All secondary PRCA may be related to the immune injury of abnormally proliferated T cells to erythroid (14-16). The patient in our study suffered from chronic liver graft-versus-host disease (GVHD), 1 year after HSCT. T cell was activated in the development of GVHD (17-19). The T cells proliferation can lead to immune impairing targeting erythroid (20, 21). In our case, EPO was used to cure the anemia at the second development of PRCA induced by LZD.
But, EPO treatment showed little effect on LZD-induced anemia. According to the manufacturer’s instruction, complete blood count should be carried out weekly for LZD therapy patients, especially for those with more than 2 weeks of LZD prevention, with concomitant drugs that can suppress bone marrow, with chronic infections or those with concomitant antibiotics (11, 22). Eric Senneville et al found that age > 58, alcoholism, concomitant diabetes and pre-existing anemia were the risk factors for LZD-induced PRCA. The age > 58 and pre-treatment hemoglobin < 105g/L were the independent risk factors for PRCA (23). In addition, Minson Q et al indicated that basic cardiovascular and urinary diseases, concomitant immunosuppressant therapy and baseline platelet count of 50-99×10^9/L were independent risk factors for 3-4 degree anemia induced by LZD (24). In our case, although the patient was relatively young and there was no cardiovascular or urinary disease, he had MDS history and underwent allo-HSCT before 2 years ago. Furthermore, he had taken azathioprine and thalidomide successively for more than 1 year for the chronic GVHD. All of these may be other potential risk factors contributing to the PRCA occurrence.

A new Italy research found that there was no obvious difference on the effect between the LZD dosage ≤ 600 mg and > 600 mg, but the side effects increased markedly in the > 600 mg dosage group (2). The two times of PRCA occurrence in our case was induced by LZD treatment at 600 mg dosage twice a day. At the second time, the dosage was halved, the CNS infection did not get worse and the anemia was slowly improved and finally got cured after LZD withdrew. It indicated that it was necessary to reduce the dose of LZD, when the side effects continued to worsen. The side effects would relieved but not disappear with LZD dose decrease.

In our case, the anemia occurred twice at day 22 and day 14 after LZD treatment. Eric Senneville et al (25) reported that the median time of anemia onset and LZD initiation was 7.4 weeks (4-16 weeks) for 45 patients which was more longer than our case. Reticulocyte was an important index that reflected the bone marrow erythroid function. Therefore, the reticulocyte might be declined earlier than peripheral anemia onset in PRCA patients. Correspondingly, routine monitor of reticulocyte for patients with long-term LZD therapy was recommended to predict the anemia occurrence. At present, no other effective methods could be taken to prevent or cure LZD-induced PRCA only when LZD was stopped. It was reported that oral Vitamin B6 could reverse LZD-induced PRCA (26), while no further investigation was taken to confirm it.

In summary, a case with PRCA twice after allo-HSCT was reported in this study. A long period LZD treatment was the primary factor resulting in PRCA. Anemia, myelosuppressants history may be other risk factors for PRCA onset. Abnormal T cell proliferation and the changes in the number of blood cells were common events in development of PRCA. Therefore, the complete blood count and reticulocyte count were necessary during LZD therapy. Besides, LZD dosage reduction and blood transfusion were effective for relieving LZD-induced PRCA. The patient with anemia would recover after LZD drug was withdrawn. However, a large number of studies should be conducted to verify our findings.

Conflict of interest
The authors have no conflict of interest to declare.

Acknowledgements
This work was supported by the National Natural Science Foundations of China (No.81071951). We wish to express our warm thanks to Fenhe (shanghai) Information Technology Co. Ltd. Their ideas and help gave a valuable added dimension to our research.

References
(1) Cohen N, Mihu CN, Seo SK, Chung D, Chou J, Heller G and Papanicolaou GA. Hematologic safety profile of linezolid in the early periengraftment period after allogeneic stem cell transplantation. *Biol. Blood Marrow Transplant.* (2009) 15: 1337-41.
(2) Sotgiu G, Centis R, Dambrosio L, Alﬀenaar JWC, Anger HA, Caminero JA, Castiglia P, De Lorenzo S, Ferrara G and Koh WJ. Efficacy, safety and tolerability
of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. *Eur. Respir. J.* (2012) 40: 1430-42.

(3) Garazzino S, Krzysztowiak A, Esposito S, Castagnola E, Plebani A, Galli L, Cellini M, Lipreri R, Scalfaro C and Bertaina C. Use of linezolid in infants and children: a retrospective multicentre study of the Italian Society for Paediatric Infectious Diseases. *J. Antimicrob. Chemother.* (2011) 66: 2393-97.

(4) Berenguer N, Ferrández O, Barbosa F, Urbina O, Espona M and Grau S. Long-term treatment with linezolid in a patient with osteomyelitis undergoing hemodialysis. *J. Chemother.* (2012) 24: 226-28.

(5) Aung FM, Lichtiger B, Bassett R, Liu P, Alousi A, Bashier S, Ciurea SO, Lima MJ, Hosing C and Kebrai F. Incidence and natural history of pure red cell aplasia in major ABO-mismatched haematopoietic cell transplantation. *Br. J. Haematol.* (2013) 160: 798-805.

(6) Jung SH, Ahn JS, Yang DH, Park HC, Bae SY, Kim YK, Kim HJ and Lee JJ. Successful treatment of pure red cell aplasia with rituximab in patients after ABO-compatible allogeneic hematopoietic stem cell transplantation. *Case Rep. Oncol.* (2012) 5: 110-13.

(7) Lim S, Bee P, Keng T and Chong Y. Resolution of epoetin-induced pure red cell aplasia 2 years later, successful re-challenge with continuous erythropoiesis receptor stimulator. *Clin. Nephrol.* (2013) 80: 227-30.

(8) Green SL, Maddox JC and Huttenbach ED. Linezolid and reversible myelosuppression. *JAMA* (2001) 285: 1291-9.

(9) Monson T, Schichman SA and Zent CS. Linezolid-induced pure red blood cell aplasia. *Clin. Infect. Dis.* (2002) 35: e29-e31.

(10) Taketani T, Kanai R, Fukuda S, Uchida Y, Yasuda K, Mishima S, Suyama T, Kodama R, Yoshino I and Kunishi H. Pure red cell precursor toxicity by linezolid in a pediatric case. *J. Pediatr. Hematol. Oncol.* (2009) 31: 684-86.

(11) Waki F, Ohnishi H, Shintani T, Uemura M, Matsumoto K, Fukumoto T, Kitakana A, Kubota Y, Yanaka T and Ishida T. Linezolid-induced pure red cell aplasia in a patient with *Staphylococcus epidermidis* infection after allogeneic stem cell transplantation. *Transplant. Infect. Dis.* (2012) 14: E1-E6.

(12) Charles RJ, Sabo KM, Kidd PG and Abkowitz JL. The pathophysiology of pure red cell aplasia: implications for therapy. *Blood* (1996) 87: 4831-38.

(13) Jaramillo E, Weyer K, Raviglione M, Lee M, Lee J and Carroll M. Linezolid for extensively drug-resistant tuberculosis. *N. Engl. J. Med.* (2013) 368: 290-90.

(14) Minami R, Izutsu K, Miyamura T, Yamamoto M and Suematsu E. A case of systemic lupus erythematosus accompanied with pure red cell aplasia. *Jpn. J. Clin. Immunol.* (2006) 29: 148-53.

(15) Hirokawa M, Sawada KI, Fujishima N, Kawano F, Kimura A, Watanabe T, Arai A, Matsu T, Nakao S and Urabe A. Acquired pure red cell aplasia associated with malignant lymphomas: a nationwide cohort study in Japan for the PRCA Collaborative Study Group. *Am. J. Hematol.* (2009) 84: 144-48.

(16) Choi JH, Oh YH and Park IK. A case of pure red cell aplasia associated with angioimmunoblastic T-cell lymphoma. *Cancer Res. Treat.* (2010) 42: 115-17.

(17) Kochenderfer J, Dudley M, Carpenter R, Kassim S, Rose J, Telford W, Hakim F, Halverson D, Fowler D and Hardy N. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. *Blood* (2013) 122: 4129-39.

(18) Trzonkowski P, Dukat-Mazurek A, Bieniaszewska M, Marek-Trzonkowska N, Dobyszuk A, Juścińska J, Dutka M, Myśliwska J and Hellmann A. Treatment of graft-versus-host disease with naturally occurring regulatory cells. *Biodrugs* (2013) 27: 605-14.

(19) Newell L, Flowers M, Gooley T, Milano F, Carpenter P, Martin P and Delaney C. Characteristics of chronic GVHD after cord blood transplantation. *Bone Marrow Transplant.* (2013) 48: 1258-90.

(20) Grey-Davies E and Dearden C. The T-cell leukemias. in: Francine Fossett. *T-Cell Lymphomas*. Springer, New York (2013) 137-53.

(21) Pantin J, Tian X, Shah AA, Kurlander R, Ramos C, Cook L, Khoo H, Stoneck D, Leitman S and Barrett J. Rapid donor T-cell engraftment increases the risk of chronic graft-versus-host disease following salvage allogeneic peripheral blood hematopoietic cell transplantation for bone marrow failure syndromes. *Am. J. Hematol.* (2013) 88: 874-82.

(22) De Rosa M, Zanardi N, Notomista E, Wichelhaus TA, Saturnino C, Varcamonti M and Soriente A. Novel promising linezolid analogues: rational design, synthesis and biological evaluation. *Eur. J. Med. Chem.* (2013) 69: 779-85.

(23) Takahashi Y, Takesue Y, Nakajima K, Ichiki K, Tsuchida T, Tatsumi S, Ishihara M, Ikeuchi H and Uchino M. Risk factors associated with the development of thrombocytopenia in patients who received linezolid therapy. *J. Infect. Chemother.* (2011) 17: 382-87.

(24) Minson Q and Gentry CA. Analysis of linezolid-associated hematologic toxicities in a large veterans affairs medical center. *Pharmacotherapy: J. Human Pharmacol. Drug Ther.* (2010) 30: 895-903.

(25) Semenuk E, Legout L, Valette M, Yazdanpanah Y, Giraud F, Beltrand E, Oberl G, Dubreuil L, Migaud H and Mouton Y. Risk factors for anaemia in patients on prolonged linezolid therapy for chronic osteomyelitis: a case-control study. *J. Antimicrob. Chemother.* (2004) 54: 798-802.

(26) Spellberg B, Yoo T and Bayer AS. Reversal of linezolid-associated cytopenias, but not peripheral neuropathy, by administration of vitamin B<sub>6</sub>. *J. Antimicrob. Chemother.* (2004) 54: 832-35.

This article is available online at http://www.ijpr.ir
Back issues?
Visit http://www.ijpr.ir
or
http://ijpr.sbmui.ac.ir